Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

NCT02726399 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Low accrual rate

Conditions

Gastric Cancer
Gastroesophageal Junction Cancer

Interventions

DRUG: Ramucirumab
DRUG: Trastuzumab
DRUG: Capecitabine
DRUG: Cisplatin

Sponsor

Memorial Sloan Kettering Cancer Center